Advertisement

Prescription of interleukin-1 inhibitors in a French adult cohort of familial Mediterranean fever

  • Antoine Fayand
    Affiliations
    Sorbonne Université, Service de médecine interne, Hôpital Tenon, Assistance Publique-Hôpitaux de Paris, Paris, France

    French Reference Center for rare Auto-Inflammatory Diseases and Amyloidosis (CEREMAIA).
    Search for articles by this author
  • Léa Savey
    Affiliations
    Sorbonne Université, Service de médecine interne, Hôpital Tenon, Assistance Publique-Hôpitaux de Paris, Paris, France

    French Reference Center for rare Auto-Inflammatory Diseases and Amyloidosis (CEREMAIA).
    Search for articles by this author
  • Stéphanie Ducharme-Bénard
    Affiliations
    Sorbonne Université, Service de médecine interne, Hôpital Tenon, Assistance Publique-Hôpitaux de Paris, Paris, France

    Service de médecine interne, Hôpital du Sacré-Cœur de Montréal, Montréal, Québec, Canada
    Search for articles by this author
  • Gilles Grateau
    Affiliations
    Sorbonne Université, Service de médecine interne, Hôpital Tenon, Assistance Publique-Hôpitaux de Paris, Paris, France

    French Reference Center for rare Auto-Inflammatory Diseases and Amyloidosis (CEREMAIA).
    Search for articles by this author
  • Sophie Georgin-Lavialle
    Correspondence
    Corresponding author.
    Affiliations
    Sorbonne Université, Service de médecine interne, Hôpital Tenon, Assistance Publique-Hôpitaux de Paris, Paris, France

    French Reference Center for rare Auto-Inflammatory Diseases and Amyloidosis (CEREMAIA).
    Search for articles by this author
Published:November 19, 2020DOI:https://doi.org/10.1016/j.ejim.2020.11.001

      Highlights

      • Colchicine can prevent attacks of familial Mediterranean Fever (FMF) in most cases
      • Interleukin-1 inhibitors are efficient in FMF patients resistant to colchicine
      • IL-1 inhibitors were frequently prescribed for AA amyloidosis FMF with kidney failure
      • IL-1 inhibitors are useful in case of acquired neoplastic or inflammatory comorbidity
      • IL-1 inhibitor can be withdrawn in FMF patients with AAA after kidney transplantation

      Keywords

      Abbreviations:

      FMF (Familial Mediterranean Fever), AAA (AA Amyloidosis), IL (Interleukin), EULAR (European League Against Rheumatism), FMF-IC (FMF with inflammatory comorbidity)
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to European Journal of Internal Medicine
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Ozen S
        • Demirkaya E
        • Erer B
        • Livneh A
        • Ben-Chetrit E
        • Giancane G
        • et al.
        EULAR recommendations for the management of familial Mediterranean fever.
        Ann Rheum Dis. 2016 Apr 1; 75: 644-651
        • Dinarello CA
        • Wolfe SM
        • Goldfinger SE
        • Dale DC
        • Alling DW
        Colchicine Therapy for Familial Mediterranean Fever.
        N Engl J Med. 1974; 291 (Oct 31): 934-937
        • Zemer D
        • Pras M
        • Sohar E
        • Modan M
        • Cabili S
        • Gafni J
        Colchicine in the prevention and treatment of the amyloidosis of familial Mediterranean fever.
        N Engl J Med. 1986; 314 (Apr 17): 1001-1005
        • Park YH
        • Wood G
        • Kastner DL
        • Chae JJ
        Pyrin Inflammasome Activation and RhoA Signaling in the Autoinflammatory Diseases FMF and HIDS.
        Nat Immunol. 2016; 17 (Aug): 914-921
        • Ben-Zvi I
        • Kukuy O
        • Giat E
        • Pras E
        • Feld O
        • Kivity S
        • et al.
        Anakinra for Colchicine-Resistant Familial Mediterranean Fever: A Randomized, Double-Blind, Placebo-Controlled Trial.
        Arthritis Rheumatol Hoboken NJ. 2017; 69: 854-862
        • De Benedetti F
        • Gattorno M
        • Anton J
        • Ben-Chetrit E
        • Frenkel J
        • Hoffman HM
        • et al.
        Canakinumab for the Treatment of Autoinflammatory Recurrent Fever Syndromes.
        N Engl J Med. 2018; 378 (17): 1908-1919
        • Livneh A
        • Langevitz P
        • Zemer D
        • Zaks N
        • Kees S
        • Lidar T
        • et al.
        Criteria for the diagnosis of familial Mediterranean fever.
        Arthritis Rheum. 1997; 40 (Oct): 1879-1885
        • Stankovic Stojanovic K
        • Delmas Y
        • Torres PU
        • Peltier J
        • Pelle G
        • Jéru I
        • et al.
        Dramatic beneficial effect of interleukin-1 inhibitor treatment in patients with familial Mediterranean fever complicated with amyloidosis and renal failure.
        Nephrol Dial Transplant Off Publ Eur Dial Transpl Assoc - Eur Ren Assoc. 2012; 27 (May): 1898-1901
        • Özçakar ZB
        • Özdel S
        • Yılmaz S
        • Kurt-Şükür ED
        • Ekim M
        • Yalçınkaya F
        Anti-IL-1 treatment in familial Mediterranean fever and related amyloidosis.
        Clin Rheumatol. 2016; 35 (Feb): 441-446
        • Trabulus S
        • Korkmaz M
        • Kaya E
        • Seyahi N
        Canakinumab treatment in kidney transplant recipients with AA amyloidosis due to familial Mediterranean fever.
        Clin Transplant. 2018; 32 (Aug): e13345